Stock listing

NASDAQ:AARD Aardvark Therapeutics, Inc. Stock

Home listing (NASDAQ) of Aardvark Therapeutics, Inc.

Follow Aardvark Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:AARD

$0.923 USD -0.077 (-7.7%)

Close on Nov 20, 2026

Past year -90.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.900 – $1.060 USDNov 20, 2026
Volume
241,067 sharesNov 20, 2026
Market cap
$20.20M USDAt the close on Nov 20, 2026 · price × 21.89M shares outstanding
52-week range
$0.900 – $16.600 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1.23M USDMedian day 191,550 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Aardvark Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:AARD · Home$0.923 USD-0.077 (-7.7%)241,067$1.000$1.060$0.900$1.000Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AARD · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.923-0.077-7.7%$1.000$1.060$0.900241,067
$1.000+0.090+9.9%$0.960$1.100$0.950486,486
$0.910-0.240-20.9%$1.160$1.210$0.906530,041
$1.150-0.110-8.7%$1.240$1.380$1.100475,501
$1.260-0.070-5.3%$1.330$1.480$1.210215,221
$1.330-0.190-12.5%$1.580$1.700$1.310402,400
$1.520-0.070-4.4%$1.580$1.615$1.510249,800
$1.590+0.220+16.1%$1.350$1.680$1.340387,500
$1.370+0.020+1.5%$1.320$1.440$1.290242,600
$1.350+0.180+15.4%$1.210$1.420$1.171682,800
$1.170+0.060+5.4%$1.100$1.180$1.090221,700
$1.110-0.150-11.9%$1.180$1.231$1.095374,600
$1.260+0.030+2.4%$1.250$1.280$1.169216,200
$1.230+0.030+2.5%$1.220$1.290$1.210263,400
$1.200-0.160-11.8%$1.370$1.396$1.200339,200
$1.360-0.080-5.6%$1.390$1.460$1.330463,800
$1.440-0.070-4.6%$1.480$1.530$1.362955,900
$1.510+0.210+16.2%$1.220$1.590$1.1762,019,000
$1.300+0.220+20.4%$1.090$1.390$1.0904,282,800
$1.080-0.310-22.3%$1.245$1.390$0.9304,957,700
$1.390-2.560-64.8%$2.990$3.000$1.39016,346,500
$3.950-0.460-10.4%$4.270$4.310$3.8901,415,300
$4.410+0.510+13.1%$3.950$4.540$3.950218,400
$3.900+0.160+4.3%$3.800$4.051$3.78066,700
$3.740-0.040-1.1%$3.750$4.050$3.640129,800
$3.780-0.080-2.1%$4.190$4.190$3.73097,200
$3.860-0.020-0.5%$3.860$3.977$3.77068,800
$3.880-0.160-4.0%$3.930$4.350$3.830126,100
$4.040-0.410-9.2%$4.440$4.630$4.030218,300
$4.450-0.310-6.5%$4.810$4.877$4.40099,900
$4.760+0.050+1.1%$4.610$4.820$4.600140,900
$4.710-0.250-5.0%$4.770$5.090$4.570316,000
$4.960-0.080-1.6%$4.950$5.330$4.690212,000
$5.040-0.180-3.4%$5.280$5.450$4.660251,900
$5.220+0.230+4.6%$5.030$5.370$5.03061,300
$4.990-0.280-5.3%$5.370$5.660$4.880147,700
$5.2700.0000.0%$5.290$5.420$5.13047,800
$5.270-0.080-1.5%$5.420$5.524$5.27028,100
$5.350+0.080+1.5%$5.210$5.390$5.00239,600
$5.270+0.210+4.2%$5.050$5.320$4.96060,600
$5.060-0.490-8.8%$5.570$5.600$5.02071,500
$5.550-0.010-0.2%$5.550$5.690$5.32596,100
$5.560-0.190-3.3%$5.740$5.740$5.41554,800
$5.750+0.180+3.2%$5.510$5.840$5.500101,300
$5.570+0.190+3.5%$5.440$5.575$5.340110,300
$5.380-0.150-2.7%$5.440$5.590$5.190129,800
$5.530+0.380+7.4%$5.320$5.770$5.190258,100
$5.150+0.130+2.6%$5.040$5.290$4.93047,900
$5.020-0.530-9.5%$5.470$5.545$5.01064,200
$5.550+0.420+8.2%$4.900$5.880$4.800216,900
$5.130+0.120+2.4%$5.110$5.540$4.975276,600
$5.010+0.090+1.8%$4.870$5.015$4.540209,400
$4.920-0.410-7.7%$5.330$5.456$4.895109,700
$5.330-0.050-0.9%$5.330$5.710$5.100164,700
$5.380-0.350-6.1%$5.720$5.991$5.150257,800
$5.730-0.220-3.7%$5.920$6.190$5.60089,300
$5.950+0.030+0.5%$6.050$6.225$5.79559,400
$5.920-0.180-3.0%$6.000$6.245$5.80785,000
$6.100+0.310+5.4%$5.700$6.155$5.300125,400
$5.790-0.830-12.5%$6.470$6.470$5.620143,000
$6.620-0.190-2.8%$6.890$7.085$6.58574,200
$6.810-0.440-6.1%$7.290$7.300$6.210111,900
$7.250+0.370+5.4%$6.940$7.310$6.490145,204
$6.880+0.060+0.9%$6.750$6.970$6.28383,299
$6.820+0.930+15.8%$5.910$6.900$5.800173,700
$5.890-0.860-12.7%$6.760$7.120$5.760250,200
Ticker
NASDAQ:AARD
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Aardvark Therapeutics, Inc. news

Aardvark Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 33 in all · newest Nov 13, 2026 · oldest 2025
Decks
4 decks · latest Oct 23, 2026

Where Aardvark Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:AARD · Home listing · This pageNASDAQUnited StatesUSD
BOATS:AARDBOATSUnited StatesUSD

Valuation

Price/book 0.3× against a median of 2.0×: 2nd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$39.58M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
3.28

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Aardvark Therapeutics, Inc. · NASDAQ:AARDUS$20.20M−US$39.58Mn/an/an/a0.3×n/a0.0×3.28
NanoGroup SA · GPW:NNGUS$21.31MUS$18.78Mn/an/an/a4.0×n/a0.0×n/a
Cel-Sci Corporation · AMEX:CVMUS$21.28MUS$14.76Mn/an/an/a1.9×n/a0.0×1.13
ZYUS Life Sciences Corporation · TSXV:ZYUSUS$20.92MUS$25.66Mn/a98.4×n/an/an/an/a-0.02
Xbrane Biopharma AB · OMXSTO:XBRANEUS$20.86MUS$23.45Mn/a1.9×n/a0.4×−49.0%0.1×n/a
Vivoryon Therapeutics N.V. · EURONEXT:VVYUS$20.48MUS$17.77Mn/an/an/a11.9×n/a0.1×n/a
Evaxion A/S · NASDAQ:EVAXUS$20.30MUS$13.40Mn/a1.8×n/a2.1×−115.1%0.8×0.78
GenSight Biologics SA · EURONEXT:SIGHTUS$20.19MUS$32.44Mn/a29,573×n/an/an/an/an/a
TransCode Therapeutics, Inc. · NASDAQ:RNAZUS$20.07MUS$15.44Mn/an/an/a0.6×n/a0.0×1.03
Adicet Bio, Inc. · NASDAQ:ACETUS$20.03MUS$5.02Mn/an/an/a0.2×n/a0.1×2.02
IGC Pharma, Inc. · AMEX:IGCUS$19.60MUS$19.19Mn/an/an/a3.0×n/a0.0×1.09
Median of the othersUS$20.39MUS$18.27M50.1×2.0×−82.1%0.0×1.06

Forecasts

4 strong buy · 5 hold · 1 sell · 1 strong sell · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
4.57 USD · Analysts' mean
EPS, year to Dec 2026
-3.21 · 9 analysts

Team and board

Officers

OfficerRole
Tien LeeChief Executive Officer
Nelson SunChief Operating Officer & Chief Financial Officer
Christopher J. KemmererEVP, Technical Operations
Dvorit SamidEVP, Medical Affairs
Justin StegeVP, Head of Project Management and Strategy
Ron LewisVP, Head of CMC
David ZhangChief Strategy Officer
Derrick LiChief Business Officer
Manasi JaimanChief Medical Officer
Victor TongManaging Director
Zhenhuan ZhengChief Research Officer

Board

DirectorRole
Jeffrey ChiVice Chairman
Roy Baynes
Susan E. GrafBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close−12.5%
Q2 2026Aug 11, 2026 · After close−8.6%
Q1 2026Apr 6, 2026−6.0%
Q4 2025Mar 23, 2026 · After close−7.3%
Q3 2025Nov 13, 2025 · After close−8.7%
Q2 2025Aug 13, 2025 · After close+0.5%
Q1 2025May 14, 2025 · After close+4.0%
Q4 2024Mar 31, 2025+7.1%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (October 2026)Technical26 slidesOct 23, 2026
Investor Presentation (January 2026)Investor deck29 slidesJan 12, 2026
ObesityWeek Investor Webinar 2025Conference65 slidesNov 6, 2025
Investor Presentation (September 2025)Investor deck22 slidesSep 3, 2025

Open Decks

IPO

Priced at US$16.00 a share on Feb 12, 2025.

Price
US$16.00 a share
Shares offered
5,888,000 shares of common stock
Offering size
US$94.2 million
Underwriters' option
Up to 883,200 more shares
Underwriters
MORGAN STANLEY, BofA SECURITIES, CANTOR, RBC CAPITAL MARKETS · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceOct 24, 2024
Filed publiclyJan 23, 2025
Amended onceFeb 6, 2025
Shares registered with an exchangeFeb 10, 2025
Declared effective by the SECFeb 12, 2025
Final prospectus, with the priceFeb 13, 2025

Open IPO · From the cover of the final prospectus (424B4) filed Feb 13, 2025

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022
Revenue0000
Cost of revenue36.0K16.0K97.0K110.0K
Gross profit-36.0K-16.0K-97.0K-110.0K
Research and development48.9M17.4M4.48M7.17M
Selling, general and administrative13.8M5.30M2.17M2.70M
Operating income-62.7M-22.8M-7.42M-11.4M
Depreciation and amortization36.0K16.0K97.0K110.0K
EBITDA-62.7M-22.8M-7.32M-11.3M
Income before tax-57.6M-20.6M-7.21M-13.6M
Income tax00
Net income-57.6M-20.6M-7.21M-13.6M
Earnings per share, basic-2.93-5.15-0.34-0.63
Earnings per share, diluted-2.93-5.15

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents47.1M61.6M9.73M15.6M
Short-term investments63.0M12.0M254.0K546.0K
Current assets111.9M74.1M10.4M16.5M
Total assets117.2M77.5M10.5M16.8M
Accounts payable2.07M2.30M1.03M259.0K
Current liabilities10.5M4.93M1.38M595.0K
Total debt441.0K779.0K162.0K262.0K
Total liabilities10.5M5.39M45.3M44.7M
Shareholders' equity106.6M-54.6M-34.8M-27.9M
Shares outstanding21.8M4.07M21.4M21.4M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-54.2M-18.1M-5.82M-10.5M
Capital spending-95.0K-109.0K00
Free cash flow-54.3M-18.2M-5.82M-10.5M
Cash from investing-49.7M-12.0M-1.00M
Cash from financing89.2M82.0M0225.0K
Share buybacks195.0K
Change in cash-14.6M51.9M-5.82M-11.3M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
8-K · Current reportNov 13, 2026ResultsSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
4 · Change in ownershipNov 10, 2026Insider tradeSEC
4 · Change in ownershipNov 10, 2026Insider tradeSEC
4 · Change in ownershipNov 10, 2026Insider tradeSEC
8-K · Current reportOct 23, 2026Current reportSEC
8-K · Current reportOct 22, 2026Current reportSEC
4 · Change in ownershipOct 8, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
All 120 filings
FilingDateTypeFiled with
8-K · Current reportOct 8, 2026Management or board changeSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
144 · Notice of proposed saleSep 11, 2026Other filingsSEC
144 · Notice of proposed saleSep 10, 2026Other filingsSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
8-K · Current reportAug 17, 2026Meeting outcomeSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
8-K · Current reportAug 11, 2026ResultsSEC
ARS · Annual report to shareholdersJul 10, 2026Annual reportSEC
DEF 14A · Proxy statementJul 10, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementJun 29, 2026Meeting noticeSEC
8-K · Current reportJun 12, 2026Management or board changeSEC
8-K · Current reportMay 14, 2026Current reportSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
EFFECT · Notice that a registration is effectiveApr 6, 2026Other filingsSEC
424B5 · ProspectusApr 3, 2026Offer documentSEC
CORRESP · Letter to the SECMar 30, 2026Other filingsSEC
UPLOAD · Letter from the SECMar 25, 2026Other filingsSEC
8-K · Current reportMar 23, 2026Material contractSEC
S-8 · Registration statement for employee plansMar 23, 2026Offer documentSEC
S-3 · Registration statementMar 23, 2026Offer documentSEC
10-K · Annual reportMar 23, 2026Annual reportSEC
8-K · Current reportMar 23, 2026ResultsSEC
8-K · Current reportFeb 27, 2026Current reportSEC
8-K · Current reportFeb 12, 2026Management or board changeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
8-K · Current reportFeb 10, 2026Current reportSEC
8-K · Current reportJan 12, 2026Current reportSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
8-K · Current reportDec 10, 2025Current reportSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportNov 13, 2025ResultsSEC
8-K · Current reportNov 5, 2025Current reportSEC
8-K · Current reportNov 4, 2025Current reportSEC
4 · Change in ownershipOct 16, 2025Insider tradeSEC
4 · Change in ownershipOct 16, 2025Insider tradeSEC
8-K · Current reportOct 8, 2025Current reportSEC
4 · Change in ownershipSep 16, 2025Insider tradeSEC
144 · Notice of proposed saleSep 15, 2025Other filingsSEC
4 · Change in ownershipSep 12, 2025Insider tradeSEC
4 · Change in ownershipSep 10, 2025Insider tradeSEC
8-K · Current reportSep 2, 2025Current reportSEC
144 · Notice of proposed saleSep 2, 2025Other filingsSEC
4 · Change in ownershipAug 29, 2025Insider tradeSEC
144 · Notice of proposed saleAug 28, 2025Other filingsSEC
S-8 · Registration statement for employee plansAug 13, 2025Offer documentSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
8-K · Current reportAug 13, 2025ResultsSEC
8-K · Current reportAug 12, 2025Current reportSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
8-K · Current reportMar 31, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeFeb 24, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 24, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 24, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
8-K · Current reportFeb 14, 2025Current reportSEC
S-8 · Registration statement for employee plansFeb 13, 2025Offer documentSEC
424B4 · ProspectusFeb 13, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveFeb 13, 2025Other filingsSEC
3 · Initial statement of ownershipFeb 12, 2025Insider tradeSEC
3 · Initial statement of ownershipFeb 12, 2025Insider tradeSEC
3 · Initial statement of ownershipFeb 12, 2025Insider tradeSEC
3 · Initial statement of ownershipFeb 12, 2025Insider tradeSEC
3 · Initial statement of ownershipFeb 12, 2025Insider tradeSEC
3 · Initial statement of ownershipFeb 12, 2025Insider tradeSEC
3 · Initial statement of ownershipFeb 12, 2025Insider tradeSEC
3 · Initial statement of ownershipFeb 12, 2025Insider tradeSEC
3 · Initial statement of ownershipFeb 12, 2025Insider tradeSEC
3 · Initial statement of ownershipFeb 12, 2025Insider tradeSEC
3 · Initial statement of ownershipFeb 12, 2025Insider tradeSEC
CERT · Exchange's certificate of listingFeb 12, 2025Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeFeb 10, 2025Other filingsSEC
CORRESP · Letter to the SECFeb 10, 2025Other filingsSEC
CORRESP · Letter to the SECFeb 10, 2025Other filingsSEC
S-1/A · Registration statement, amendedFeb 6, 2025Offer documentSEC
CORRESP · Letter to the SECJan 31, 2025Other filingsSEC
S-1 · Registration statementJan 23, 2025Offer documentSEC
DRSLTR · Letter to the SEC with a draftDec 20, 2024Other filingsSEC
DRS/A · Draft registration statement, amendedDec 20, 2024Offer documentSEC
UPLOAD · Letter from the SECDec 10, 2024Other filingsSEC
DRSLTR · Letter to the SEC with a draftNov 27, 2024Other filingsSEC
DRS/A · Draft registration statement, amendedNov 27, 2024Offer documentSEC
UPLOAD · Letter from the SECNov 21, 2024Other filingsSEC
DRS · Draft registration statementOct 24, 2024Offer documentSEC
DMay 15, 2024Other filingsSEC
DJun 7, 2021Other filingsSEC
DMay 24, 2019Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Aardvark Therapeutics, Inc.’s releases · as of Nov 2, 2026

Common shares
21,891,271
Fully diluted
21,891,271

Fully diluted

LineSharesAs of
Common shares21,891,271Nov 2, 2026

Share count over time

CountShares
Nov 2, 202621,891,271

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Decheng Capital LLC3.92M17.9%US$20.6MSep 30, 2026
Laurion Capital Management LP1.03M4.7%US$5.45MSep 30, 2026
Citadel975K4.5%US$5.14MSep 30, 2026
EcoR1 Capital, LLC720K3.3%US$3.79MSep 30, 2026
Vanguard639K2.9%US$3.37MSep 30, 2026
ExodusPoint Capital Management, LP316K1.4%US$1.67MSep 30, 2026
BlackRock195K0.89%US$1.03MSep 30, 2026
Geode Capital139K0.63%US$733KSep 30, 2026
Marshall Wace, LLP132K0.60%US$697KSep 30, 2026
Jacobs Levy Equity Management, Inc130K0.59%US$686KSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Two Sigma130K0.59%US$683KSep 30, 2026
AQR Capital Management LLC114K0.52%US$601KSep 30, 2026
Raymond James Financial Inc92,8920.42%US$490KSep 30, 2026
Cantor Fitzgerald, L. P.91,6820.42%US$483KSep 30, 2026
Velan Capital Investment Management LP85,8680.39%US$453KSep 30, 2026
Jane Street68,6360.31%US$362KSep 30, 2026
Millennium62,4540.29%US$329KSep 30, 2026
Susquehanna60,9760.28%US$321KSep 30, 2026
State Street57,5730.26%US$303KSep 30, 2026
J. Goldman & Co LP54,1270.25%US$285KSep 30, 2026
Adage Capital Partners Gp, L.L.C.50,0000.23%US$264KSep 30, 2026
D. E. Shaw & Co., Inc.40,5580.19%US$214KSep 30, 2026
Simplex Trading, LLC37,5380.17%US$198KSep 30, 2026
Point72 Asset Management, L.P.35,4560.16%US$187KSep 30, 2026
XTX Topco Ltd35,2460.16%US$186KSep 30, 2026
Northern Trust28,0800.13%US$148KSep 30, 2026
Barclays25,7920.12%US$136KSep 30, 2026
Cresset Asset Management, LLC24,0000.11%US$126KSep 30, 2026
Smith, Moore & Co.23,7250.11%US$125KSep 30, 2026
Empowered Funds, LLC23,6020.11%US$124KSep 30, 2026
Bridgeway Capital Management, LLC23,6020.11%US$124KSep 30, 2026
Fidelity18,9000.09%US$99,603Sep 30, 2026
Dimensional17,7100.08%US$93,332Sep 30, 2026
Schonfeld Strategic Advisors LLC15,9420.07%US$84,013Sep 30, 2026
Verdad Advisers, LP14,9530.07%US$78,802Sep 30, 2026
Quadrature Capital Ltd12,2710.06%US$64,668Sep 30, 2026
Gsa Capital Partners LLP11,8080.05%US$62,000Sep 30, 2026
Goldman Sachs10,4650.05%US$55,151Sep 30, 2026
Trexquant Investment LP10,3290.05%US$54,434Sep 30, 2026
Ieq Capital, LLC10,2940.05%US$54,249Sep 30, 2026
Abel Hall, LLC10,0660.05%US$53,048Sep 30, 2026
BNP Paribas9,9710.05%US$52,547Sep 30, 2026
Morgan Stanley7,4290.03%US$39,150Sep 30, 2026
Steward Partners Investment Advisory, LLC6,9300.03%US$36,521Sep 30, 2026
Arax Advisory Partners4,2100.02%US$22,187Sep 30, 2026
China Universal Asset Management Co., Ltd.3,9930.02%US$21,363Sep 30, 2026
Tower Research Capital LLC (TRC)2,9910.01%US$15,763Sep 30, 2026
JPMorgan1,630<0.01%US$8,721Sep 30, 2026
UBS1,436<0.01%US$7,568Sep 30, 2026
Russell Investments Group, Ltd.1,239<0.01%US$6,530Sep 30, 2026

This page holds 50 of 74 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund409K1.9%US$2.35MJun 30, 2026
Vanguard Extended Market Index Fund140K0.64%US$809KJun 30, 2026
iShares Biotechnology ETF89,1240.41%US$513KJun 30, 2026
Fidelity Extended Market Index Fund66,7470.30%US$274KMay 31, 2026
Vanguard Russell 2000 Index Fund64,9810.30%US$267KMay 31, 2026
iShares Micro-Cap ETF42,6150.19%US$245KJun 30, 2026
Ultra-Small Company Market Fund24,0000.11%US$138KJun 30, 2026
Fidelity Total Market Index Fund22,6330.10%US$93,022May 31, 2026
ALPS Medical Breakthroughs ETF22,4390.10%US$92,224May 31, 2026
Fidelity Series Total Market Index Fund18,7350.09%US$77,001May 31, 2026
All 33 holders
HolderSharesOf the companyValueAs of
Fidelity Nasdaq Composite Index Fund15,4830.07%US$63,635May 31, 2026
Vanguard Balanced Index Fund8,8670.04%US$51,074Jun 30, 2026
VIP Disciplined Small Cap Portfolio7,9800.04%US$45,965Jun 30, 2026
Vanguard Russell 2000 Growth Index Fund6,7190.03%US$27,615May 31, 2026
Vanguard Institutional Total Stock Market Index Fund4,9510.02%US$28,518Jun 30, 2026
Small Cap Index Fund4,6360.02%US$19,054May 31, 2026
Invesco Russell 2000 Dynamic Multifactor ETF4,4790.02%US$18,409May 31, 2026
Vanguard Russell 2000 Value Index Fund4,2640.02%US$17,525May 31, 2026
1290 VT Micro Cap Portfolio2,6790.01%US$15,431Jun 30, 2026
Bridge Builder Small/Mid Cap Value Fund2,4740.01%US$14,250Jun 30, 2026
AQR Small Cap Multi-Style Fund1,503<0.01%US$8,657Jun 30, 2026
Vanguard Russell 3000 Index Fund1,472<0.01%US$6,050May 31, 2026
Bridge Builder Small/Mid Cap Growth Fund1,274<0.01%US$7,338Jun 30, 2026
Invesco Nasdaq Biotechnology ETF1,150<0.01%US$4,727May 31, 2026
ProShares Ultra Nasdaq Biotechnology804<0.01%US$3,304May 31, 2026
Siit Extended Market Index Fund800<0.01%US$3,288May 31, 2026
ProShares Russell 2000 High Income ETF600<0.01%US$2,466May 31, 2026
ProShares UltraPro Russell2000475<0.01%US$1,952May 31, 2026
ProShares Ultra Russell2000469<0.01%US$1,928May 31, 2026
Blackstone Alternative Multi-Strategy Fund200<0.01%US$1,152Jun 30, 2026
Knights of Columbus U.S. ALL CAP INDEX FUND72<0.01%US$475Jul 31, 2026
ProShares Hedge Replication ETF12<0.01%US$49May 31, 2026
ProShares Russell 2000 Dynamic Buffer ETF3<0.01%US$12May 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Sun Nelson
Officer: See Remarks
Sale62,000USD 5.18US$321KSep 11, 2026
Sun Nelson
Officer: See Remarks
Sale14,754USD 5.00US$73,770Sep 10, 2026

Big stakes

StakeStakeSharesDateFiling
Tien-Li Lee13.70%2.98MMar 31, 2025Schedule 13G
Vickers Venture Fund VI Pte. Ltd.9.58%2.05MFeb 12, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Susan E. Graf
Other companies: CG Oncology, Inc. (Director · Since at least Jan 24, 2024); Epizyme Inc (Chief Business Officer · Apr 25, 2016 – Feb 9, 2018 · Past)
Board Member · Since at least Feb 12, 2025
Jeffrey Chi
Other companies: Scilex Holding Company (Director · Jan 6, 2021 – Jan 6, 2021 · Past)
Vice Chairman · Since at least Feb 12, 2025
Victor Edward Tong Jr
Other companies: CG Oncology, Inc. (Director · Since at least Jan 24, 2024)
Director · Since at least Feb 12, 2025
Victor Tong
Other companies: CG Oncology, Inc. (Managing Director, Decheng Capital · Since at least Nov 5, 2026)
Managing Director · Since at least Nov 5, 2026
Bryan JonesChief Operating Officer · Since at least Feb 12, 2025
Christopher J. KemmererEVP, Technical Operations · Since at least Nov 4, 2026
David ZhangChief Strategy Officer · Since at least Oct 8, 2026
Derrick LiChief Business Officer · Since at least Feb 12, 2026
Dvorit SamidEVP, Medical Affairs · Since at least Nov 4, 2026
Justin StegeVP, Head of Project Management and Strategy · Since at least Nov 4, 2026
All 16 people
PersonSeat
Manasi JaimanChief Medical Officer · Since at least Dec 10, 2025
Nelson SunChief Operating Officer & Chief Financial Officer · Since at least Feb 12, 2025
Ron LewisVP, Head of CMC · Since at least Nov 4, 2026
Roy BaynesDirector · Since at least Nov 4, 2026
Tien LeeChief Executive Officer · Since at least Oct 23, 2026
Zhenhuan ZhengChief Research Officer · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Aardvark Therapeutics, Inc.